Skip to content
BiologicalX

Comparison

Alpha-GPC vs Tirzepatide

Side-by-side of Alpha-GPC and Tirzepatide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Alpha-GPC

  • Choline donor supplement, roughly 40% choline by weight; crosses blood-brain barrier efficiently
  • Replicated small gains in attention and reaction time at 300 to 600 mg in healthy adults
  • Standard prescription cognitive medication in much of Europe (Gliatilin) at 1,200 mg/day for vascular cognitive impairment
  • ASCOMALVA trial (n=210) showed cognitive preservation when added to donepezil over 24 months
  • Increases acute power output (~14%, single trial) and transient growth hormone secretion at 600 mg
  • TMAO production raises a contested cardiovascular concern at chronic high doses

Tirzepatide

  • Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
  • SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
  • Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
  • Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
  • GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
  • Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this

Side-by-side

Attribute Alpha-GPC Tirzepatide
Category supplement pharmaceutical
Also known as L-Alpha glycerylphosphorylcholine, choline alfoscerate, GPC, alpha-glyceryl phosphorylcholine Mounjaro, Zepbound, LY3298176
Half-life (hr) 4 120
Typical dose (mg) 600 10
Dosing frequency 1 to 3 times daily weekly
Routes oral subcutaneous
Onset (hr) 1 24
Peak (hr) 2 72
Molecular weight 257.22 4813.45
Molecular formula C8H20NO6P C225H348N48O68
Mechanism Hydrolyzed to free choline and glycerophosphate after absorption; choline supports acetylcholine and phosphatidylcholine synthesis in CNS. Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits.
Legal status Dietary supplement (US); prescription medication in much of Europe Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound)
WADA status allowed allowed
DEA / Rx OTC supplement Rx only (not a controlled substance)
Pregnancy Insufficient data; choline generally recommended in pregnancy Not recommended; discontinue 2 months before planned pregnancy
CAS 28319-77-9 2023788-19-2
PubChem CID 71920 156588324
Wikidata Q411478 Q105099794

Safety profile

Alpha-GPC

Common side effects

  • mild GI upset
  • headache
  • dizziness
  • occasional insomnia with evening dosing

Contraindications

  • established cardiovascular disease (TMAO concern)
  • concurrent strong anticholinergic therapy

Interactions

  • anticholinergic medications: partial mutual antagonism(minor)
  • cholinesterase inhibitors (donepezil): additive cholinergic effect, basis for ASCOMALVA protocol(minor)
  • scopolamine: partial counteraction of anticholinergic effect(minor)

Tirzepatide

Common side effects

  • nausea
  • diarrhea
  • vomiting
  • constipation
  • decreased appetite
  • injection-site reactions
  • fatigue
  • abdominal pain

Contraindications

  • personal or family history of medullary thyroid carcinoma
  • multiple endocrine neoplasia type 2
  • pregnancy
  • history of pancreatitis (use caution)
  • severe gastroparesis

Interactions

  • insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
  • sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
  • oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
  • oral contraceptives: reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation(moderate)
  • warfarin: monitor INR due to altered absorption(moderate)

Which Should You Take?

Alpha-GPC comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Tirzepatide is the right call when one of the conditionals below applies.

  • If your priority is focus or working memory, pick Alpha-GPC.
  • If your priority is athletic performance, pick Alpha-GPC.
  • If your priority is metabolic health and glucose control, pick Tirzepatide.
  • If your priority is fat loss, pick Tirzepatide.

Edge case: If you want to avoid prescription-only, Alpha-GPC is the more accessible choice.

Default choice: Alpha-GPC. Lower friction to source, and broader goal coverage. Reach for Tirzepatide only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Alpha-GPC and Tirzepatide?

Alpha-GPC and Tirzepatide differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Alpha-GPC or Tirzepatide?

Alpha-GPC half-life is 4 hours; Tirzepatide half-life is 120 hours.

Can you stack Alpha-GPC with Tirzepatide?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper